(Tarrytown, NY) -- Regeneron is seeking FDA approval for its antibody cocktail to be used as a preventive treatment for COVID-19.  

The FDA already granted emergency use authorization for the treatment to be used in severe cases, mostly for those hospitalized with the virus.  

New clinical trial data shows Regeneron's treatment reduced the risk of becoming infected by 81-percent.  

Regeneron said just eleven people out of 753 who had been exposed and received their treatment became infected with COVID-19.  

Infected individuals also cleared the virus faster with the therapy.

Suggested Content